Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.

Advanced practice model improves pharmacy practice in ED

30 Sep 2020

Implementation of an advanced pharmacy practice model has “maximized opportunities” for pharmacists to provide direct patient care, practice “at the top of their license,” and promote safe and effective use of medications, according to a retrospective descriptive study.

The authors quantified clinical activities performed by pharmacists in an advanced pharmacy practice model in the emergency department (ED). They collected and reviewed data extracted from January 2015 to August 2017 from the department of pharmacy’s electronic documentation system and the hospital’s electronic medical record.

Cost savings were obtained from the system with adaptation from the previous literature and had been validated by the institution’s administration as an acceptable reflection of the impact for activity.

A total of 4,106 clinical activities had been participated in by the ED pharmacy team, resulting in a cumulative cost avoidance of $5,387,679. Pharmacotherapy consult (63.6 percent) and response to medical emergencies (20.7 percent) were the most common clinical activities that the pharmacy team provided overall.

ED clinicians placed a total of 16,219 medication orders, which were prospectively reviewed, and accepted 379 interventions. Median turnaround times for medication verification were 2 minutes (interquartile range [IQR], 1–6 minutes) for 2015, 2 minutes (IQR, 1–6 minutes) for 2016, and 2 minutes (IQR, 1–5 minutes) for 2017.

A research programme led by the ED pharmacotherapist published 14 peer-reviewed publications, based mainly on pharmacy practice or use of pharmacotherapy for acute pain.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.